Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SUVN 502

Drug Profile

SUVN 502

Alternative Names: M1; M1 of SUVN-502; SUVN502; SVN-502

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Indoles; Piperazines; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia

Highest Development Phases

  • Phase II Alzheimer's disease; Schizophrenia
  • Preclinical Dementia
  • Discontinued Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease

Most Recent Events

  • 05 Oct 2018 Discontinued - Phase-I for Alzheimer's disease in Switzerland (PO)
  • 05 Oct 2018 Discontinued - Phase-I for Attention-deficit hyperactivity disorder in Switzerland (PO)
  • 05 Oct 2018 Discontinued - Phase-I for Cognition disorders in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top